Remains Opposed to Sale of Acceleron to Merck (MRK) at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company,...
KNOXVILLE, TN, Oct. 28, 2021 -- Provectus today announced that updated response, safety, and immune correlative data from the Company’s ongoing Phase 1b clinical trial of cancer immunotherapy PV-10, in combination with Keytruda, for the treatment of advanced cutaneous melanoma in patients refractory to immune checkpoint blockade will be presented at the SMR 2021 Virtual Congress, which is bei...
The acquisition of BEPATIENT puts Alira Health firmly on the path of merging biopharma, medical, and digital technology development with medical care using patient data. Alira Health, a leading technology-enabled services provider, announced that it has acquired BEPATIENT, a European healthcare technology company. Every healthcare company says that they are patient-centric.
Paris, October 28, 2021 Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER Q3 2021 sales grew double digit to €10.4 billion due to strong growth from Dupixent®, Vaccines and CHC Q3 2021 business EPS growth of 19.1% at CER driven by sales performance and efficiencies Progress on Corporate Social Responsibility strategy Key milestone and regulatory achievem...
20,000 sq. ft. biofabrication facility will operate from Houstons East End Maker Hub Volumetric, a Houston-based biofabrication start-up company developing biomaterials and advanced 3D bioprinting technologies, announced today it has entered into an agreement to be acquired by 3D Systems (DDD) in a deal structured as $45 million closing payment, with up to $355 million additional opportunity linked ...
LAS VEGAS, Oct. 27, 2021 DelveInsight's Hepatic Encephalopathy Market report delivers an in-depth understanding of current treatment practices, emerging drugs, Hepatic Encephalopathy market share of the individual therapies, current and forecasted Hepatic Encephalopathy market size from 2018 to 2030 segmented into the 7MM [The United States, EU5, and Japan]. Some of the key takeaways from the H...
LONDON, Oct. 27, 2021 Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.
CHICAGO, Oct. 27, 2021 Axio Biologics has joined Supply Clinic's vast list of authorized sellers passing additional savings on to Dental Practitioners. To bring Doctors better pricing and high-quality products, Axio Biologics works closely with Manufacturers, allowing them to cut the costs of Distributors, and pass those savings on to Dentists.
RALEIGH, N.C., Oct. 27, 2021 Inceptor Bio, today announced an agreement with Arranta Bio for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio's planned oncology clinical trials.
− Acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging γδT cells for the potential treatment of solid tumors and hematological malignancies − As result of successful “build-to-buy” collaboration, Takeda to exercise its right to acquire GammaDelta Therapeutics for a pre-negotiated upfront and future potential milestone ...
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
